Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...
In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...
Ouro’s series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK ...
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...
On Friday, San Francisco-based Ouro emerged from stealth revealing $120 million in funding from backers that include GSK, which helped form the young company. “Fundamentally, we think this could ...
Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...
Ouro Medicines’ name is short for ouroboros, an ancient symbol of a snake eating itself for eternal recycling, rebirth and renewal. A San Francisco startup, founded by Big Pharma player GSK plc ...
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...